New hope for children with relapsing malaria: tafenoquine trial launches in PNG
NCT ID NCT07403643
First seen Feb 16, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study tests a single-dose drug called tafenoquine in 60 children with uncomplicated vivax malaria in Papua New Guinea. The goal is to see if it safely eliminates both blood-stage parasites and hidden liver-stage parasites that cause relapses. Researchers will measure how the drug works in the body and check for side effects like anemia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNCOMPLICATED MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alexishafen Health Centre
Madang, Madang Province, MP511, Papua New Guinea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.